Tasso is an emerging healthcare company that is transforming the traditional blood collection process with a more convenient and virtually painless approach that focuses on the patient.

Tasso's operational goals, keeping the company on track to achieve each defined milestone.

Tasso was founded in 2012 by Ben Casavant and Erwin Berthier. The company is headquartered in Seattle, Washington.


Tasso’s lead product, Tasso OnDemand, allows people to self-collect blood from the comfort and privacy of their home and mail the samples back to the lab for analysis. By integrating blood tests into the virtual care experience, Tasso expands the amount of data that can be collected to support care delivery and analytics.


Tasso's devices enable users with a simple method for collection of clinical quality blood at any convenient time or location, eliminating the burden of clinic appointments while increasing access to remote populations.


Tasso’s innovative, virtually painless blood collection technology with an integrated logistics platform provides leading pharmaceutical companies, academic institutions, and payers with unprecedented access to actionable health data.


Tasso is backed by RA Capital Management, Foresite Capital, Merck Global Health Innovation Fund, D.E. Shaw group, Senvest, InCube, SVB Innovation Fund, and others. The company raised $100M in Series B round on Dec 16, 2021. This brings Tasso's total funding to $132M to date.



  • Year founded: 2012
  • Funding Info: $132M over 7 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Seattle
  • State: Washington
  • Country: United States
Related businesses